Compare SHASUN PHARMA with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA GLENMARK PHARMA SHASUN PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 123.9 10.1 1,225.4% View Chart
P/BV x 8.5 1.4 590.4% View Chart
Dividend Yield % 0.2 0.7 33.5%  

Financials

 SHASUN PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
GLENMARK PHARMA
Mar-19
SHASUN PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs94712 13.2%   
Low Rs46484 9.4%   
Sales per share (Unadj.) Rs214.2349.6 61.3%  
Earnings per share (Unadj.) Rs5.332.8 16.3%  
Cash flow per share (Unadj.) Rs15.844.3 35.7%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %1.40.3 427.5%  
Book value per share (Unadj.) Rs53.3198.6 26.9%  
Shares outstanding (eoy) m56.62282.17 20.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.31.7 19.1%   
Avg P/E ratio x13.118.2 71.9%  
P/CF ratio (eoy) x4.413.5 32.8%  
Price / Book Value ratio x1.33.0 43.6%  
Dividend payout %18.76.1 307.2%   
Avg Mkt Cap Rs m3,958168,625 2.3%   
No. of employees `000NA12.0 0.0%   
Total wages/salary Rs m2,16420,561 10.5%   
Avg. sales/employee Rs ThNM8,196.0-  
Avg. wages/employee Rs ThNM1,708.1-  
Avg. net profit/employee Rs ThNM768.5-  
INCOME DATA
Net Sales Rs m12,12798,655 12.3%  
Other income Rs m2292,081 11.0%   
Total revenues Rs m12,356100,736 12.3%   
Gross profit Rs m1,00915,858 6.4%  
Depreciation Rs m5943,259 18.2%   
Interest Rs m4153,346 12.4%   
Profit before tax Rs m23011,335 2.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m-733,756 -1.9%   
Profit after tax Rs m3029,250 3.3%  
Gross profit margin %8.316.1 51.8%  
Effective tax rate %-31.733.1 -95.5%   
Net profit margin %2.59.4 26.6%  
BALANCE SHEET DATA
Current assets Rs m6,88466,968 10.3%   
Current liabilities Rs m8,45640,211 21.0%   
Net working cap to sales %-13.027.1 -47.8%  
Current ratio x0.81.7 48.9%  
Inventory Days Days6283 74.0%  
Debtors Days Days10881 132.5%  
Net fixed assets Rs m4,97033,322 14.9%   
Share capital Rs m113282 40.1%   
"Free" reserves Rs m2,87555,770 5.2%   
Net worth Rs m3,02056,052 5.4%   
Long term debt Rs m1,81735,738 5.1%   
Total assets Rs m13,347132,888 10.0%  
Interest coverage x1.64.4 35.4%   
Debt to equity ratio x0.60.6 94.4%  
Sales to assets ratio x0.90.7 122.4%   
Return on assets %5.49.5 56.7%  
Return on equity %10.016.5 60.6%  
Return on capital %13.317.8 74.8%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728NA-   
Fx inflow Rs m5,84362,998 9.3%   
Fx outflow Rs m2,17322,859 9.5%   
Net fx Rs m3,66940,140 9.1%   
CASH FLOW
From Operations Rs m39813,242 3.0%  
From Investments Rs m-1,635-6,990 23.4%  
From Financial Activity Rs m1,309-7,387 -17.7%  
Net Cashflow Rs m71-2,971 -2.4%  

Share Holding

Indian Promoters % 39.2 48.3 81.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 6.9 52.2%  
FIIs % 17.6 34.4 51.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 10.5 377.1%  
Shareholders   20,750 56,727 36.6%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   PANACEA BIOTECH  BIOCON   FULFORD INDIA  NATCO PHARMA  AJANTA PHARMA  

Compare SHASUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Open Marginally Higher; Healthcare Stocks Witness Buying(09:30 am)

Asian share markets are trading on a negative note today as Japanese and Hong Kong shares show losses. The Nikkei 225 is down 0.79% while the Hang Seng is down 1.73%.

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS